Novartis refines India unit strategy, shares in focus on SIX trading
23.06.2026 - 20:54:18 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:53.
Novartis (CH0012005267) remains closely watched on SIX Swiss Exchange as investors track the strategic options for its listed India subsidiary. The Swiss blue chip is a key constituent of the SMI and a major weight in European healthcare indices.
Strategic review of Novartis India
In early 2024 Novartis AG began a strategic review of its roughly 70 percent stake in Novartis India Limited, exploring options for the business including a potential stake sale according to local filings and market commentary. An overview of Novartis India from Bitget highlights that the review has remained a central theme for the unit this year.
Novartis India trades on both the BSE and NSE in Mumbai under the ticker NOVARTIND, giving the Swiss parent direct exposure to one of the fastest-growing pharmaceutical markets. Shares of Novartis India last traded around the local morning session on June 23, 2026, per BSE data.
Analyst views on the Novartis stock
On the Swiss line, Novartis is widely covered by European and US brokers, with a predominantly positive stance. MarketScreener data show a majority of Buy ratings on the stock and a consensus target price above the current SIX level, underlining confidence in the pipeline and capital return profile. The MarketScreener consensus page lists recent research from houses including Goldman Sachs, UBS and JPMorgan.
US investors access Novartis through the NYSE-listed ADR under the ticker NVS, where the stock recently traded around 152.80 US dollars, up about 2.6 percent on the day according to MarketBeat. MarketBeat news on NVS combines ADR price data with recent headlines and broker commentary.
All news and analysis on the Novartis shares
Further details on Novartis, its share price performance and past ad-hoc releases are available in the dedicated topic section and via the company’s Investor Relations site.
How Novartis earns its money
Novartis generates most of its revenue with patented prescription medicines in areas such as cardiology, immunology, neuroscience and oncology. Key recent growth drivers include the heart-failure drug Entresto and the gene therapy Zolgensma, alongside mature franchises in ophthalmology and multiple sclerosis.
Where the stock trades today
The Novartis shares (CH0012005267) most recently traded on SIX Swiss Exchange at 121.96 Swiss francs at 10:03 on 2026-06-23, according to finanzen.ch data, implying a low double-digit percentage gain over the past 12 months.
Novartis at a glance
- Company: Novartis AG
- ISIN: CH0012005267
- WKN: 904278
- Ticker: NOVN
- Trading venue: SIX Swiss Exchange (primary listing)
- Price (as of 2026-06-23, 10:03): 121.96 CHF
- Market cap: around 260 billion CHF (as of 2026-06-23, based on recent SIX prices and shares outstanding)
- Sector / industry: Healthcare / Pharmaceuticals
- Index membership: SMI, STOXX Europe 50, STOXX Europe 600
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, an offer, or a recommendation to buy or sell any financial instrument. Investors should conduct their own research and consider their individual financial situation before making investment decisions.
